News | drug discovery
31-01-2012 | reMYND receives a positive tax ruling on the income from its Roche collaboration
In the press | reMYND NV has received a positive ruling from the Belgian Tax Authorities. The ruling stipulates that the upfront license fee, all milestone payments and royalties linked to Roche Basel will qualify for the patent income deduction under Articles 205 WIB 92.
29-09-2011 | The strategic alliance between Roche and reMYND is nominated for a Scrip Award
In the press | The strategic Alliance between Roche and reMYND to develop novel therapeutics that could slow down neurodegeneration in Parkinson’s and Alzheimer’s patients is nominated for the Scrip Award “Best Partnership Alliance”. The winners will be announced in London on November 3rd, 2011. The Scrip Awards celebrate each year Excellence in the Pharmaceutical Industry.
17-08-2011 | reMYND’s grant from the Michael J Fox Foundation in SciBX
In the press | The Science-Business eXchange (SciBX, a publication by the makers of BioCentury and Nature) devoted in its recent publication an article to the role the Michael J Fox Foundation for Parkinson’s Research has been playing in the development of PD therapeutics. reMYND’s lead Parkinson program features in this article as a prime example of such support.
27-06-2011 | IWT helps to accelerate reMYND’s Diabetes program with a grant of 1.48 million EUR for 2011-2012
Press release | reMYND NV today announced that it has received a grant of 1.48 million EUR from IWT, the Flemish agency for Innovation by Science and Technology, to accelerate its Diabetes program.
15-11-2010 | Review in Nature highlights reMYND's discovery platform
In the November 2010 issue of the high impact journal Nature Reviews Drug Discovery, the News&Analysis column has been entirely devoted to the growing interest in targeting protein misfolding to therapeutically treat both rare and common diseases. The column highlights amongst others reMYND’s technology platform and the recently announced Roche-reMYND collaboration for the development of first-in-class disease-modifying treatments for Parkinson's and Alzheimer's disease.
07-09-2010 | Roche and reMYND's DDD enter into a strategic alliance to develop first-in-class disease-modifying treatments for Parkinson's and Alzheimer's disease
Press Release | Roche (SIX: RO, ROG; OTCQX: RHHBY) and reMYND today announced that they have entered into an agreement to develop novel therapeutics that could slow down neurodegeneration in Parkinson’s and Alzheimer’s patients by inhibiting α-synuclein and tau toxicity.
02-06-2010 | Ablynx and reMYND settle dispute amicably
Press Release | Ablynx nv [Euronext Brussels: ABLX] and reMYND nv announced today that they have reached a settlement concerning a dispute relating to a collaboration agreement to discover and commercialize new Nanobodies® which Ablynx and reMYND entered into in 2003.
10-12-2009 | reMYND receives a grant of 0.9 million EUR from IWT
reMYND receives a grant of 0.9 million EUR from the Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT).
21-07-2009 | reMYND awarded by the Michael J. Fox Foundation
reMYND is one of the nine biotech and pharmaceutical companies that have been awarded by the Michael J. Fox Foundation for Parkinson's Research in July 2009.
10-12-2008 | reMYND receives a grant of almost 1 million EUR from IWT
reMYND receives a grant of almost 1 million EUR from the Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT).
15-11-2008 | reMYND's Lead Alzheimer drug demonstrates neuroprotection
reMYND's Lead Alzheimer drug demonstrates neuroprotection in 2 transgenic animal models of TAU and Amyloid bèta pathology.
15-03-2008 | Lead product for treating Parkinson's Disease demonstrates efficacy
Lead product for treating Parkinson's Disease demonstrates efficacy in 3 different animal models of Parkinson's Disease: a chemically-induced model and 2 different transgenic α-synuclein mouse models.
26-03-2007 | reMYND's Parkinson's disease drug discovery program reaches breakthrough
Press Release | reMYND nv announced today that it has reached a breakthrough in its drug discovery program aimed at identifying disease-modifying drugs for the treatment of Parkinson's disease. A large family of analogous compounds (coded ReS9-S) were found to possess cytoprotective properties in cellular model systems. Efficacy studies with one ReS9-S lead in a well known animal model of Parkinson's disease corroborated these highly promising results.
